Enovis (NYSE:ENOV) Rating Increased to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Enovis from hold to buy, adding to a generally bullish analyst backdrop. The stock now carries a Moderate Buy consensus with an average price target of $45.17.
• Enovis recently reported better-than-expected first-quarter results, posting EPS of $0.89 versus the $0.82 estimate and revenue of $589.15 million versus $572.02 million. Revenue also rose 5.4% year over year.
• The company reaffirmed 2026 guidance, including EPS of $3.52 to $3.73 and revenue of $2.3 billion to $2.4 billion, while also maintaining a free cash flow conversion target of greater than 25%.

Enovis (NYSE:ENOV - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Sunday.

Several other equities research analysts also recently issued reports on ENOV. Wells Fargo & Company cut their price objective on Enovis from $42.00 to $40.00 and set an "overweight" rating on the stock in a report on Friday. Zacks Research raised Enovis from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, March 4th. William Blair began coverage on shares of Enovis in a research note on Friday, April 17th. They set an "outperform" rating on the stock. Weiss Ratings reissued a "sell (e+)" rating on shares of Enovis in a research note on Friday, April 10th. Finally, BTIG Research lifted their price objective on shares of Enovis from $41.00 to $43.00 and gave the company a "buy" rating in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $45.17.

Enovis Price Performance

Enovis stock opened at $26.52 on Friday. The company's 50 day simple moving average is $23.86 and its 200-day simple moving average is $25.80. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.04 and a current ratio of 2.04. Enovis has a 1 year low of $21.00 and a 1 year high of $37.85. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -1.33 and a beta of 1.41.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping analysts' consensus estimates of $0.82 by $0.07. The firm had revenue of $589.15 million during the quarter, compared to analysts' expectations of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the company posted $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, equities research analysts expect that Enovis will post 3.62 earnings per share for the current year.

Insider Transactions at Enovis

In related news, insider Oliver Engert acquired 1,000 shares of the firm's stock in a transaction dated Friday, February 27th. The stock was acquired at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the purchase, the insider owned 43,640 shares of the company's stock, valued at $1,112,820. This represents a 2.35% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders bought 5,000 shares of company stock valued at $121,983. 2.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENOV. AQR Capital Management LLC lifted its position in shares of Enovis by 12.5% during the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company's stock worth $2,363,000 after purchasing an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Enovis by 37.6% in the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company's stock valued at $10,226,000 after buying an additional 73,116 shares in the last quarter. Empowered Funds LLC lifted its holdings in Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company's stock worth $249,000 after buying an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock worth $40,000 after acquiring an additional 707 shares in the last quarter. Finally, Amundi lifted its stake in Enovis by 24,405.0% during the second quarter. Amundi now owns 9,802 shares of the company's stock worth $328,000 after purchasing an additional 9,762 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company's stock.

Key Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported first-quarter EPS of $0.89, topping estimates of $0.82, while revenue of $589.15 million also beat expectations. Revenue rose 5.4% year over year, signaling solid demand and execution. Article Title
• Positive Sentiment: The company reaffirmed 2026 free cash flow conversion of greater than 25%, suggesting management still sees healthy cash generation despite Middle East and tariff headwinds. Article Title
• Neutral Sentiment: Enovis also reiterated full-year 2026 guidance, with EPS of $3.52 to $3.73 and revenue of $2.3 billion to $2.4 billion, which was roughly in line with analyst expectations and may reassure investors about the company’s near-term outlook. Article Title
• Neutral Sentiment: Wells Fargo lowered its price target on Enovis to $40 from $42, but kept an overweight rating, indicating continued upside potential despite a slightly more cautious valuation view. Article Title

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.